Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Discovery & Translation

Science Spotlight: Engineered CD47 protects CAR T cells from macrophages and more

BioCentury’s roundup of translational innovations

June 6, 2024 12:09 AM UTC

A team led by serial entrepreneur and  Stanford University professor Crystal Mackall revealed a method to increase the antitumor efficacy of anti-CD47 mAbs for solid tumors.

Blocking of the CD47-SIRPA pathway, by which cancers send a ‘don’t eat me’ signal to the immune system, can lead to increased macrophage-mediated phagocytosis of tumor cells, but has led to limited efficacy in the clinic. To further increase tumor cell killing, the Nature paper authors combined an anti-CD47 mAb with tumor-targeted CAR T cells. The strategy was stymied, however, by rapid macrophage-mediated clearance of the CAR Ts...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article